Application
Fig1: Western blot analysis of RALA on human RALA recombinant protein using anti-RALA antibody at 1/1,000 dilution.Application
Fig2: Western blot analysis of RALA on HEK293 (1) and RALA-hIgGFc transfected HEK293 (2) cell lysate using anti-RALA antibody at 1/1,000 dilution.Application
Fig3: Western blot analysis of RALA on different cell lysate using anti-RALA antibody at 1/1,000 dilution. Positive control： Lane1: HepG2 Lane2: MCF-7 Lane3: A549 Lane4: K562 Lane5: Raji Lane6: MOLT4 Lane7: Hela Lane8: COS7 Lane9: NIH/3T3Application
Fig4:ICC staining RALA (green) and Actin filaments (red) in Hela cells. The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.Application
Fig5: Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissue using anti-RALA antibody. Counter stained with hematoxylin.Application
Fig6: Immunohistochemical analysis of paraffin-embedded human bladder cancer tissue using anti-RALA antibody. Counter stained with hematoxylin.Application
Fig7:Flow cytometric analysis of MCF-7 cells with RALA antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).| Product Name | RALA |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | MGC48949 antibody Ral a antibody Ral A protein antibody RAL antibody RALA antibody RALA_HUMAN antibody Ras family small GTP binding protein RALA antibody RAS like protein A antibody Ras related protein RalA antibody Ras-related protein Ral-A antibody v ral simian leukemia viral oncogene homolog A (ras related) antibody v ral simian leukemia viral oncogene homolog A antibody |
| Product description | Ral A and Ral B constitute a distinct subfamily of Ras-related GTPases (i.e., GDP/GTP binding proteins). Ral proteins are activated by a unique nucleotide exchange factor, Ral GDS, and deactivated by a distinct GTPase-activating protein. Unlike Ras proteins, Ral A and Ral B fail to induce transformed foci when activated variants are expressed in various recipient cells. A potential downstream target of Ral, designated Ral BP-1, has been shown to contain a Rho-GTPase-activating domain. This Rho-GTPase-activating domain interacts preferentially with the Rho family member Cdc42. A Ras/Ral signaling pathway has been reported to mediate phospholipase D (PLD) activation by v-Src, thus indicating PLD as another downstream target of Ral A. |
| Immunogen | Recombinant protein |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG1 |
| Host Species | Mouse |
| Tested Applications | WBICCIHCFC |
| WB:1:500-1:2,000 ICC:1:50-1:200 IHC:1:50-1:200 FC:1:100-1:200 |
|
| Species Reactivity | HumanMouseMonkey |
| Concentration | 2mg/ml |
| Alternative Names | MGC48949 antibody Ral a antibody Ral A protein antibody RAL antibody RALA antibody RALA_HUMAN antibody Ras family small GTP binding protein RALA antibody RAS like protein A antibody Ras related protein RalA antibody Ras-related protein Ral-A antibody v ral simian leukemia viral oncogene homolog A (ras related) antibody v ral simian leukemia viral oncogene homolog A antibody |
|---|---|
| Molecular Weight(MW) | 24 kDa |
| Cellular Localization | Cell surface. Cell membrane. Cleavage furrow. |
| SwissProt ID | P11233 |
|---|
Application
Fig1: Western blot analysis of RALA on human RALA recombinant protein using anti-RALA antibody at 1/1,000 dilution.
Application
Fig2: Western blot analysis of RALA on HEK293 (1) and RALA-hIgGFc transfected HEK293 (2) cell lysate using anti-RALA antibody at 1/1,000 dilution.
Application
Fig3: Western blot analysis of RALA on different cell lysate using anti-RALA antibody at 1/1,000 dilution. Positive control： Lane1: HepG2 Lane2: MCF-7 Lane3: A549 Lane4: K562 Lane5: Raji Lane6: MOLT4 Lane7: Hela Lane8: COS7 Lane9: NIH/3T3
Application
Fig4:ICC staining RALA (green) and Actin filaments (red) in Hela cells. The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.
Application
Fig5: Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissue using anti-RALA antibody. Counter stained with hematoxylin.
Application
Fig6: Immunohistochemical analysis of paraffin-embedded human bladder cancer tissue using anti-RALA antibody. Counter stained with hematoxylin.
Application
Fig7:Flow cytometric analysis of MCF-7 cells with RALA antibody at 1/100 dilution (green) compared with an unlabelled control (cells without incubation with primary antibody; red).| Positive Control | Human RALA recombinant protein, RALA-hIgGFc transfected HEK293 cell lysate, HepG2, MCF-7, A549, K562, Raji, MOLT4, Hela, COS7, NIH/3T3, human bladder cancer tissue, human ovarian cancer tissue. |
|---|---|
| Application Notes | WB:1:500-1:2,000 ICC:1:50-1:200 IHC:1:50-1:200 FC:1:100-1:200 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
